Trial Profile

A Study of RM-718 Weekly Formulation in Healthy Subjects With Obesity and in Patients With Obesity Due to MC4R Impairment

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 10 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RM 718 (Primary)
Indications Obesity; Prader-Willi syndrome
Focus Adverse reactions; First in man
Sponsors Rhythm

Most Recent Events

26 Feb 2026 According to a Rhythm Pharmaceuticals media release, On December 11, 2025, the Company announced that it has initiated a Part D arm in the Phase 1/2 trial of MC4R agonist RM-718 that will enroll up to 20 patients with PWS.
26 Feb 2026 According to a Rhythm Pharmaceuticals media release, the company anticipate to complete enrollment in the Phase 1/2, Part D trial evaluating RM-718 in PWS in the second half of 2026.
22 Dec 2025 Planned number of patients changed from 120 to 150.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com